TScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at Wedbush

TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "outperform" rating reissued by equities research analysts at Wedbush in a report released on Tuesday,RTT News reports. They presently have a $7.00 price target on the stock. Wedbush's price objective would indicate a potential upside of 399.64% from the stock's previous close.

A number of other research firms have also recently commented on TCRX. Morgan Stanley reissued an "overweight" rating and set a $10.00 target price on shares of TScan Therapeutics in a research report on Friday, March 14th. Needham & Company LLC reissued a "buy" rating and issued a $9.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Barclays dropped their target price on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Thursday, March 6th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $9.33.

TScan Therapeutics Stock Down 6.6 %

NASDAQ TCRX traded down $0.10 during trading hours on Tuesday, hitting $1.40. The company had a trading volume of 200,996 shares, compared to its average volume of 358,823. The firm's 50 day moving average is $1.54 and its 200 day moving average is $2.79. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $9.69. The company has a market capitalization of $79.28 million, a price-to-earnings ratio of -1.33 and a beta of 1.06.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. Sell-side analysts anticipate that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Prudential Financial Inc. acquired a new stake in shares of TScan Therapeutics during the 4th quarter worth approximately $32,000. China Universal Asset Management Co. Ltd. bought a new stake in TScan Therapeutics in the fourth quarter valued at $32,000. ProShare Advisors LLC acquired a new position in shares of TScan Therapeutics during the fourth quarter valued at $40,000. Wells Fargo & Company MN grew its position in shares of TScan Therapeutics by 41.1% during the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after acquiring an additional 5,694 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of TScan Therapeutics in the 4th quarter worth about $59,000. Institutional investors and hedge funds own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.